UK regulatory context
MHRA vs EMA vs FDA — why approval status differs
Educational explainer on how the UK MHRA, European EMA and US FDA differ in their roles, approval pathways and timing, and what that means for the availability of incretin and metabolic peptide medicines.
Three regulators, three jurisdictions
The UK Medicines and Healthcare products Regulatory Agency (MHRA), the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) each assess the same trial evidence under their own legal frameworks and clinical contexts. A medicine that is FDA-approved is not automatically UK-licensed; a UK-licensed medicine is not automatically available on the NHS without a separate NICE technology appraisal. For how these three-way differences map onto prescription-only, investigational and research-only status, see the UK regulatory status hub.
Why approval status differs
- Different jurisdictions. Each regulator authorises only for its own territory. Post-Brexit, the MHRA operates an independent UK pathway distinct from the EMA.
- Different evidence considerations. Each regulator weighs trial designs, comparator standards-of-care, and post-marketing commitments within its own clinical and public-health context.
- Different timing. FDA approvals frequently precede EMA and MHRA decisions, but not always; some indications reach the UK before the US.
- Different label scope. The same molecule may have different indications, populations, dosing schedules and warnings across MHRA, EMA and FDA labels.
Practical implications for UK readers
- FDA approval of an investigational compound is meaningful evidence-of-evidence, but it does not legalise UK access or UK use outside an authorised research setting.
- EMA approval may not yet be MHRA approval; check the MHRA register and the current UK SmPC for the specific product.
- NHS availability is a separate question from MHRA licensing. NICE technology appraisals (e.g., for tirzepatide and semaglutide for weight management) set the NHS access criteria within the licensed indication.
The investigational layer
Compounds like retatrutide, cagrilintide, CagriSema, survodutide, pemvidutide, mazdutide and cotadutide are investigational across all three regulators at the time of review. Investigational status means well-defined human trials are taking place under regulator oversight, but the molecule is not licensed for therapeutic use and must not be used outside an authorised research setting.
- FDA approval does not equal MHRA approval.
- MHRA approval does not equal NHS availability.
- EMA approval before Brexit transition does not automatically translate into post-Brexit UK status — check the MHRA register.
- Approval for one indication does not establish approval (or safety) for any other indication.
Related UK regulatory topics
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK medicines regulator — primary source for UK approval decisions
- Regulatory document (MHRA/EMA/FDA)European Medicines Agency
EU medicines regulator — primary source for EMA approval decisions
- Regulatory document (MHRA/EMA/FDA)FDA — U.S. Food and Drug Administration
US medicines regulator — primary source for FDA approval decisions